Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPA vs DHA Effects on Thrombogenesis in Dyslipidemia
NCT06494488Phase 1Recruiting
- Sponsor
- The Miriam Hospital
- Start
- Jul 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in hypertriglyceridemia and atherogenic dyslipidemia (AD) comparing DHA Group with EPA Group (2 arms). Primary endpoint: Percentage of Platelet Aggregation Area Under the Curve (AUC) Over Time at 8 weeks. Started Jul 2025; status: recruiting.
02
Drugs
eicosapentaenoic aciddocosahexaenoic acid
03
Conditions
hypertriglyceridemiaatherogenic dyslipidemia (AD)
Beyond the preview
Go deeper on NCT06494488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06494488.